ASCO 2023 | Future endeavours with ADCs in bladder cancer

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, reflects on the use of antibody-drug conjugates (ADCs) in the management of patients with urothelial carcinoma, including enfortumab vedotin and sacituzumab govetican as later-stage therapies, as well as future endevaours to move these novel therapies in earlier lines of treatment, touching on the ongoing EV-302 trial (NCT04223856) which is evaluating enfortumab vedotin and pembrolizumab in the front-line setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.